Dr. Gary Kirsh on This Exciting Phase in Prostate Cancer Care

Gary Kirsh, MD
Published: Friday, Nov 04, 2016


Gary Kirsh, MD, President of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses this exciting phase in prostate cancer care. Kirsh shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.

Kirsh says while experts thought prostate cancer care was rapidly advancing 5 or 6 years ago, the next few years will be even more exciting, with new oral androgen receptor agents, PARP inhibitors coming forward, and perhaps new immunotherapies.

While there have been several new agents made available in the past 4 or 5 years, Kirsh says he believes the number of products will more than double in the next 5 years.

Gary Kirsh, MD, President of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses this exciting phase in prostate cancer care. Kirsh shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.

Kirsh says while experts thought prostate cancer care was rapidly advancing 5 or 6 years ago, the next few years will be even more exciting, with new oral androgen receptor agents, PARP inhibitors coming forward, and perhaps new immunotherapies.

While there have been several new agents made available in the past 4 or 5 years, Kirsh says he believes the number of products will more than double in the next 5 years.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x